Incretin drugs effect on epigenetic machinery: New potential therapeutic implications in preventing vascular diabetic complications

Abstract

The effect of GLP-1R agonists on DNA methylation levels of NF-κB and SOD2 genes in human aortic endothelial cells exposed to high glucose and in diabetic patients treated and not with incretin-based drugs, was evaluated. Methylation levels, mRNA and protein expression of NF-κB and SOD2 genes were measured in human endothelial cells exposed to high glucose for 7 days and treated with GLP-1R agonists. Methylation status of NF-κB and SOD2 promoter was also analyzed in 128 diabetics and 116 nondiabetics and correlated with intima media thickness (ITM), an early marker of atherosclerotic process. Cells exposed to high glucose showed lower NF-κB and SOD2 methylation levels, increased NF-κB and reduced SOD2 expression compared to normal glucose cells. Co-treatment with GLP-1 agonists prevented methylation and genes expression changes induced by high glucose. Both high glucose and incretins exposure increased DNA methyltransferases and demethylases levels. In diabetics, incretin treatment resulted a significant predictor of NF-κB DNA methylation, independently of age, sex, body mass index (BMI), glucose and plasma lipid levels. NF-κB DNA methylation inversely correlated with IMT after adjusting for multiple covariates. Our results firstly provide new evidences of an additional mechanism by which incretin drugs could prevent vascular diabetic complications. K E Y W O R D S atherosclerosis progression, DNA methylation, incretin based drugs, type 2 diabetes 2 | SCISCIOLA et AL.

Adiponectin Related Vascular and Cardiac Benefits in Obesity: Is There a Role for an Epigenetically Regulated Mechanism?

“…In a large population (n = 356) and using quantitative pyrosequencing-based analysis, our results showed an independent predictive role of adiponectin on IL-6 and NF-kB DNA methylation levels firstly, thus supporting the hypothesis of an involvement of epigenetic factors in the anti-inflammatory effect of adiponectin. Pyrosequencing-based analysis was suitable for measuring subtle methylation changes at more than one CpG site and thus for detecting DNA methylation more accurately in the region (35)(36)(37). Unfortunately, our data non-allow us to determine which epigenetic mediators of DNA methylation modifications (DNMTs, TET, etc.)…”

Dysfunctional High-Density Lipoproteins in Type 2 Diabetes Mellitus: Molecular Mechanisms and Therapeutic Implications

“…As described for metformin, GLP-1 receptor agonists have been shown to play a role in reverting epigenetic modifications induced by T2DM, possibly preventing atherosclerosis and vascular diabetic complications [ 150 , 151 ].…”

Roles and Mechanisms of DNA Methylation in Vascular Aging and Related Diseases

“…Therefore, DNA methylation-based therapies can benefit diabetes and reduce diabetes-related vascular complications. Cells treated with high glucose exhibited lower DNA methylation levels of NF- κ B and SOD2 , while co-treatment with GLP-1 agonists reversed these effects by decreasing DNMT1 and DNMT3a mRNA and protein levels and increasing TET2 mRNA and protein levels ( Scisciola et al, 2020 ). Additionally, it has been reported that SGLT2 gene is hypomethylated in kidney proximal tubules, which suggest that SGLT2 inhibitors may be a DNA methylation modulators ( Marumo et al, 2015 ).…”